Actions of SPM in regulating host responses in arthritis

Molecular Aspects of Medicine

Volumn 58, Issue , 2017, Pages 57-64

  Perretti, Mauro ^a   Norling, Lucy V ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIRHEUMATIC AGENT; CD59 ANTIGEN; CYCLOOXYGENASE 2 INHIBITOR; FISH OIL; MARESIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; OPIATE; RESOLVIN; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; AUTACOID;

ARTHRITIS; BIOSYNTHESIS; CHONDROCYTE; COLLAGEN-INDUCED ARTHRITIS; CONSTIPATION; DIET SUPPLEMENTATION; DRUG DEPENDENCE; DRUG EFFICACY; FIBROBLAST; FIBROMYALGIA; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFECTIOUS ARTHRITIS; MACROPHAGE; MAST CELL; META ANALYSIS (TOPIC); NAUSEA; NEUTROPHIL; NONHUMAN; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCLAST; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SEDATION; SIDE EFFECT; T LYMPHOCYTE; TENDINITIS; TISSUE REGENERATION; VOMITING; ALTERNATIVE MEDICINE; ANIMAL; BONE; CARTILAGE; DRUG EFFECT; HOST PATHOGEN INTERACTION; METABOLISM; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS; ARTHRITIS, RHEUMATOID; BONE AND BONES; CARTILAGE; COMPLEMENTARY THERAPIES; FATTY ACIDS, OMEGA-3; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATION MEDIATORS;

EID: 85018761101     PISSN: 00982997     EISSN: 18729452     Source Type: Journal    
DOI: 10.1016/j.mam.2017.04.005     Document Type: Review

References (101)

1. Albandar, J.M., Epidemiology and risk factors of periodontal diseases. Dent. Clin. North Am. 49:3 (2005), 517–532 v-vi.
2. Arita, M., Bianchini, F., Aliberti, J., Sher, A., Chiang, N., Hong, S., et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201:5 (2005), 713–722.
3. Arnardottir, H.H., Dalli, J., Norling, L.V., Colas, R.A., Perretti, M., Serhan, C.N., Resolvin D3 is dysregulated in arthritis and reduces arthritic inflammation. J. Immunol. 197:6 (2016), 2362–2368.
4. Bacon, P.A., Townend, J.N., Nails in the coffin: increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Arthritis Rheum. 44:12 (2001), 2707–2710.
5. Bang, S., Yoo, S., Yang, T.J., Cho, H., Kim, Y.G., Hwang, S.W., Resolvin D1 attenuates activation of sensory transient receptor potential channels leading to multiple anti-nociception. Br. J. Pharmacol. 161:3 (2010), 707–720.
6. Bang, S., Yoo, S., Yang, T.J., Cho, H., Hwang, S.W., 17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception. Br. J. Pharmacol. 165:3 (2012), 683–692.
7. Barden, A.E., Moghaddami, M., Mas, E., Phillips, M., Cleland, L.G., Mori, T.A., Specialised pro-resolving mediators of inflammation in inflammatory arthritis. Prostagl. Leukot. Essent. Fat. Acids 107 (2016), 24–29.
8. Birnbaum, Y., Ye, Y., Lin, Y., Freeberg, S.Y., Nishi, S.P., Martinez, J.D., et al. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation 114:9 (2006), 929–935.
9. Blaho, V.A., Zhang, Y., Hughes-Hanks, J.M., Brown, C.R., 5-Lipoxygenase-deficient mice infected with Borrelia burgdorferi develop persistent arthritis. J. Immunol. 186:5 (2011), 3076–3084.
10. Calder, P.C., Session 3: joint nutrition society and Irish nutrition and dietetic institute symposium on 'nutrition and autoimmune disease' PUFA, inflammatory processes and rheumatoid arthritis. Proc. Nutr. Soc. 67:4 (2008), 409–418.
11. Calder, P.C., Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim. Biophys. Acta 1851:4 (2015), 469–484.
12. Caliendo, G., Cirino, G., Santagada, V., Wallace, J.L., Synthesis and biological effects of hydrogen sulfide (H2S): development of H2S-releasing drugs as pharmaceuticals. J. Med. Chem. 53:17 (2010), 6275–6286.
13. Ceko, M., Bushnell, M.C., Gracely, R.H., Neurobiology underlying fibromyalgia symptoms. Pain Res. Treat., 2012, 2012, 585419.
14. Chabane, N., Zayed, N., Benderdour, M., Martel-Pelletier, J., Pelletier, J.P., Duval, N., et al. Human articular chondrocytes express 15-lipoxygenase-1 and -2: potential role in osteoarthritis. Arthritis Res. Ther., 11(2), 2009, R44.
15. Chan, M.M., Moore, A.R., Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J. Immunol. 184:11 (2010), 6418–6426.
16. Chiang, N., Bermudez, E.A., Ridker, P.M., Hurwitz, S., Serhan, C.N., Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. U. S. A. 101:42 (2004), 15178–15183.
17. Chiang, N., Shinohara, M., Dalli, J., Mirakaj, V., Kibi, M., Choi, A.M., et al. Inhaled carbon monoxide accelerates resolution of inflammation via unique proresolving mediator-heme oxygenase-1 circuits. J. Immunol. 190:12 (2013), 6378–6388.
18. Colas, R.A., Shinohara, M., Dalli, J., Chiang, N., Serhan, C.N., Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am. J. Physiol. Cell Physiol. 307:1 (2014), C39–C54.
19. Corsiero, E., Nerviani, A., Bombardieri, M., Pitzalis, C., Ectopic lymphoid structures: powerhouse of autoimmunity. Front. Immunol., 7, 2016, 430.
20. Croft, A.P., Naylor, A.J., Marshall, J.L., Hardie, D.L., Zimmermann, B., Turner, J., et al. Rheumatoid synovial fibroblasts differentiate into distinct subsets in the presence of cytokines and cartilage. Arthritis Res. Ther., 18(1), 2016, 270.
21. Dakin, S.G., Martinez, F.O., Yapp, C., Wells, G., Oppermann, U., Dean, B.J., et al. Inflammation activation and resolution in human tendon disease. Sci. Transl. Med., 7(311), 2015, 311 ra173.
22. Dakin, S.G., Buckley, C.D., Al-Mossawi, M.H., Hedley, R., Martinez, F.O., Wheway, K., et al. Persistent stromal fibroblast activation is present in chronic tendinopathy. Arthritis Res. Ther., 19(1), 2017, 16.
23. Dalli, J., Norling, L.V., Renshaw, D., Cooper, D., Leung, K.Y., Perretti, M., Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles. Blood 112:6 (2008), 2512–2519.
24. Dalli, J., Consalvo, A.P., Ray, V., Di Filippo, C., D'Amico, M., Mehta, N., et al. Proresolving and tissue-protective actions of annexin A1-based cleavage-resistant peptides are mediated by formyl peptide receptor 2/lipoxin A4 receptor. J. Immunol. 190:12 (2013), 6478–6487.
25. Dalli, J., Zhu, M., Vlasenko, N.A., Deng, B., Haeggstrom, J.Z., Petasis, N.A., et al. The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J. official Publ. Fed. Am. Soc. Exp. Biol. 27:7 (2013), 2573–2583.
26. Dalli, J., Kraft, B.D., Colas, R.A., Shinohara, M., Fredenburgh, L.E., Hess, D.R., et al. Proresolving lipid mediator profiles in baboon pneumonia are regulated by inhaled carbon monoxide. Am. J. Respir. Cell Mol. Biol. 53:3 (2015), 314–325.
27. de Pablo, P., Chapple, I.L., Buckley, C.D., Dietrich, T., Periodontitis in systemic rheumatic diseases. Nat. Rev. Rheumatol. 5:4 (2009), 218–224.
28. Dufton, N., Hannon, R., Brancaleone, V., Dalli, J., Patel, H.B., Gray, M., et al. Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J. Immunol. 184:5 (2010), 2611–2619.
29. Edwards, S.W., Hallett, M.B., Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol. Today 18:7 (1997), 320–324.
30. Ehrentraut, H., Clambey, E.T., McNamee, E.N., Brodsky, K.S., Ehrentraut, S.F., Poth, J.M., et al. CD73+ regulatory T cells contribute to adenosine-mediated resolution of acute lung injury. FASEB J. official Publ. Fed. Am. Soc. Exp. Biol. 27:6 (2013), 2207–2219.
31. Feldmann, M., Maini, R.N., The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatol. Oxf. 38:Suppl. 2 (1999), 3–7.
32. Feldmann, M., Maini, R.N., Perspectives from masters in rheumatology and autoimmunity: can we get closer to a cure for rheumatoid arthritis?. Arthritis Rheumatol. 67:9 (2015), 2283–2291.
33. Gao, L., Faibish, D., Fredman, G., Herrera, B.S., Chiang, N., Serhan, C.N., et al. Resolvin E1 and chemokine-like receptor 1 mediate bone preservation. J. Immunol. 190:2 (2013), 689–694.
34. Gasser, O., Schifferli, J.A., Activated polymorphonuclear neutrophils disseminate anti-inflammatory microparticles by ectocytosis. Blood 104:8 (2004), 2543–2548.
35. Gheorghe, K.R., Korotkova, M., Catrina, A.I., Backman, L., af Klint, E., Claesson, H.E., et al. Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids. Arthritis Res. Ther., 11(3), 2009, R83.
36. Giera, M., Ioan-Facsinay, A., Toes, R., Gao, F., Dalli, J., Deelder, A.M., et al. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. Biochimica biophysica acta 1821:11 (2012), 1415–1424.
37. Hashimoto, A., Hayashi, I., Murakami, Y., Sato, Y., Kitasato, H., Matsushita, R., et al. Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis. J. rheumatology 34:11 (2007), 2144–2153.
38. Hasturk, H., Kantarci, A., Ohira, T., Arita, M., Ebrahimi, N., Chiang, N., et al. RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis. FASEB J. 20:2 (2006), 401–403.
39. Hasturk, H., Kantarci, A., Goguet-Surmenian, E., Blackwood, A., Andry, C., Serhan, C.N., et al. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J. Immunol. 179:10 (2007), 7021–7029.
40. Headland, S.E., Jones, H.R., Norling, L.V., Kim, A., Souza, P.R., Corsiero, E., et al. Neutrophil-derived microvesicles enter cartilage and protect the joint in inflammatory arthritis. Sci. Transl. Med., 7(315), 2015, 315 ra190.
41. Herova, M., Schmid, M., Gemperle, C., Hersberger, M., ChemR23, the receptor for chemerin and resolvin E1, is expressed and functional on M1 but not on M2 macrophages. J. Immunol. 194:5 (2015), 2330–2337.
42. Herrera, B.S., Ohira, T., Gao, L., Omori, K., Yang, R., Zhu, M., et al. An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption. Br. J. Pharmacol. 155:8 (2008), 1214–1223.
43. Hollingsworth, J.W., Siegel, E.R., Creasey, W.A., Granulocyte survival in synovial exudate of patients with rheumatoid arthritis and other inflammatory joint diseases. Yale J. Biol. Med. 39:5 (1967), 289–296.
44. Huang, J., Burston, J.J., Li, L., Ashraf, S., Mapp, P.I., Bennett, A.J., et al. Targeting the D-series resolvin receptor system for the treatment of osteoarthritic pain. Arthritis Rheumatol. 69:5 (2016), 996–1008.
45. Kelly, S., Humby, F., Filer, A., Ng, N., Di Cicco, M., Hands, R.E., et al. Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients. Ann. Rheum. Dis. 74:3 (2015), 611–617.
46. Klarenbeek, N.B., Guler-Yuksel, M., van der Kooij, S.M., Han, K.H., Ronday, H.K., Kerstens, P.J., et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann. Rheum. Dis. 70:6 (2011), 1039–1046.
47. Klein, C.P., Sperotto, N.D., Maciel, I.S., Leite, C.E., Souza, A.H., Campos, M.M., Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice. Neuropharmacology 86 (2014), 57–66.
48. Konig, M.F., Abusleme, L., Reinholdt, J., Palmer, R.J., Teles, R.P., Sampson, K., et al. Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. Sci. Transl. Med., 8(369), 2016, 369 ra176.
49. Kronke, G., Katzenbeisser, J., Uderhardt, S., Zaiss, M.M., Scholtysek, C., Schabbauer, G., et al. 12/15-lipoxygenase counteracts inflammation and tissue damage in arthritis. J. Immunol. 183:5 (2009), 3383–3389.
50. Lee, C.T., Teles, R., Kantarci, A., Chen, T., McCafferty, J., Starr, J.R., et al. Resolvin E1 reverses experimental periodontitis and dysbiosis. J. Immunol. 197:7 (2016), 2796–2806.
51. Leon, H., Shibata, M.C., Sivakumaran, S., Dorgan, M., Chatterley, T., Tsuyuki, R.T., Effect of fish oil on arrhythmias and mortality: systematic review. BMJ, 337, 2008, a2931.
52. Lima-Garcia, J.F., Dutra, R.C., da Silva, K., Motta, E.M., Campos, M.M., Calixto, J.B., The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br. J. Pharmacol. 164:2 (2011), 278–293.
53. Lobo, B.W., Lima, C.K., Teixeira, M.S., Silva, N.L., Takiya, C.M., Ramos, M.F., et al. Fish oil attenuates persistent inflammatory pain in rats through modulation of TNF-alpha and resolvins. Life Sci. 152 (2016), 30–37.
54. Mas, E., Croft, K.D., Zahra, P., Barden, A., Mori, T.A., Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin. Chem. 58:10 (2012), 1476–1484.
55. McCauley, L.K., Dalli, J., Koh, A.J., Chiang, N., Serhan, C.N., Cutting edge: parathyroid hormone facilitates macrophage efferocytosis in bone marrow via proresolving mediators resolvin D1 and resolvin D2. J. Immunol. 193:1 (2014), 26–29.
56. McInnes, I.B., Schett, G., Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7:6 (2007), 429–442.
57. Miles, E.A., Calder, P.C., Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. Br. J. Nutr. 107:Suppl. 2 (2012), S171–S184.
58. Millar, N.L., Murrell, G.A., McInnes, I.B., Inflammatory mechanisms in tendinopathy - towards translation. Nat. Rev. Rheumatol. 13:2 (2017), 110–122.
59. Mirakaj, V., Dalli, J., Granja, T., Rosenberger, P., Serhan, C.N., Vagus nerve controls resolution and pro-resolving mediators of inflammation. J. Exp. Med. 211:6 (2014), 1037–1048.
60. Mohr, W., Westerhellweg, H., Wessinghage, D., Polymorphonuclear granulocytes in rheumatic tissue destruction. III. an electron microscopic study of PMNs at the pannus-cartilage junction in rheumatoid arthritis. Ann. Rheum. Dis. 40:4 (1981), 396–399.
61. Monach, P.A., Mathis, D., Benoist, C., The K/BxN arthritis model. Curr. Protoc. Immunol., 81, 2008 (Chapter 15):Unit 15.22:15.22.1–15.22.12.
62. Montero-Melendez, T., Madeira, M.F., Norling, L.V., Alsam, A., Curtis, M.A., da Silva, T.A., et al. Association between periodontal disease and inflammatory arthritis reveals modulatory functions by melanocortin receptor type 3. Am. J. Pathol. 184:8 (2014), 2333–2341.
63. Morris, T., Stables, M., Colville-Nash, P., Newson, J., Bellingan, G., de Souza, P.M., et al. Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways. Proc. Natl. Acad. Sci. U. S. A. 107:19 (2010), 8842–8847.
64. Newson, J., Stables, M., Karra, E., Arce-Vargas, F., Quezada, S., Motwani, M., et al. Resolution of acute inflammation bridges the gap between innate and adaptive immunity. Blood 124:11 (2014), 1748–1764.
65. Norling, L.V., Serhan, C.N., Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination. J. Intern. Med. 268:1 (2010), 15–24.
66. Norling, L.V., Spite, M., Yang, R., Flower, R.J., Perretti, M., Serhan, C.N., Cutting edge: humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J. Immunol. 186:10 (2011), 5543–5547.
67. Norling, L.V., Dalli, J., Flower, R.J., Serhan, C.N., Perretti, M., Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler. Thromb. Vasc. Biol. 32:8 (2012), 1970–1978.
68. Norling, L.V., Headland, S.E., Dalli, J., Arnardottir, H.H., Haworth, O., Jones, H.R., et al. Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis. JCI Insight, 1(5), 2016, e85922.
69. Oh, S.F., Dona, M., Fredman, G., Krishnamoorthy, S., Irimia, D., Serhan, C.N., Resolvin E2 formation and impact in inflammation resolution. J. Immunol. 188:9 (2012), 4527–4534.
70. Pavlov, V.A., Tracey, K.J., The vagus nerve and the inflammatory reflex–linking immunity and metabolism. Nat. Rev. Endocrinol. 8:12 (2012), 743–754.
71. Perretti, M., Leroy, X., Bland, E.J., Montero-Melendez, T., Resolution pharmacology: opportunities for therapeutic innovation in inflammation. Trends Pharmacol. Sci. 36:11 (2015), 737–755.
72. Perretti, M., Cooper, D., Dalli, J., Norling, L.V., Immune resolution mechanisms in inflammatory arthritis. Nat. Rev. Rheumatol. 13:2 (2017), 87–99.
73. Pham, C.T., Neutrophil serine proteases: specific regulators of inflammation. Nat. Rev. Immunol. 6:7 (2006), 541–550.
74. Psychogios, N., Hau, D.D., Peng, J., Guo, A.C., Mandal, R., Bouatra, S., et al. The human serum metabolome. PLoS One, 6(2), 2011, e16957.
75. Queiroz-Junior, C.M., Madeira, M.F., Coelho, F.M., de Oliveira, C.R., Candido, L.C., Garlet, G.P., et al. Experimental arthritis exacerbates Aggregatibacter actinomycetemcomitans-induced periodontitis in mice. J. Clin. Periodontol. 39:7 (2012), 608–616.
76. Raza, K., Buckley, C.E., Salmon, M., Buckley, C.D., Treating very early rheumatoid arthritis. Best. Pract. Res. Clin. Rheumatol. 20:5 (2006), 849–863.
77. Ryan, S., Psychological effects of living with rheumatoid arthritis. Nurs. Stand 29:13 (2014), 52–59.
78. Sasaki, A., Fukuda, H., Shiida, N., Tanaka, N., Furugen, A., Ogura, J., et al. Determination of omega-6 and omega-3 PUFA metabolites in human urine samples using UPLC/MS/MS. Anal. Bioanal. Chem. 407:6 (2015), 1625–1639.
79. Scher, J.U., Abramson, S.B., Periodontal disease, Porphyromonas gingivalis, and rheumatoid arthritis: what triggers autoimmunity and clinical disease?. Arthritis Res. Ther., 15(5), 2013, 122.
80. Scher, J.U., Ubeda, C., Equinda, M., Khanin, R., Buischi, Y., Viale, A., et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum. 64:10 (2012), 3083–3094.
81. Schwab, J.M., Chiang, N., Arita, M., Serhan, C.N., Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447:7146 (2007), 869–874.
82. Serhan, C.N., Pro-resolving lipid mediators are leads for resolution physiology. Nature 510:7503 (2014), 92–101.
83. Serhan, C.N., Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. FASEB J. 31:4 (2017), 1273–1288.
84. Serhan, C.N., Hong, S., Gronert, K., Colgan, S.P., Devchand, P.R., Mirick, G., et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196:8 (2002), 1025–1037.
85. Siebert, S., Tsoukas, A., Robertson, J., McInnes, I., Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol. Rev. 67:2 (2015), 280–309.
86. Simopoulos, A.P., Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 21:6 (2002), 495–505.
87. Sodin-Semrl, S., Taddeo, B., Tseng, D., Varga, J., Fiore, S., Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J. Immunol. 164:5 (2000), 2660–2666.
88. Sperling, R.I., Weinblatt, M., Robin, J.L., Ravalese, J. 3rd, Hoover, R.L., House, F., et al. Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. Arthritis Rheum. 30:9 (1987), 988–997.
89. Spite, M., Norling, L.V., Summers, L., Yang, R., Cooper, D., Petasis, N.A., et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461:7268 (2009), 1287–1291.
90. Svensson, C.I., Zattoni, M., Serhan, C.N., Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing. J. Exp. Med. 204:2 (2007), 245–252.
91. Titos, E., Rius, B., Gonzalez-Periz, A., Lopez-Vicario, C., Moran-Salvador, E., Martinez-Clemente, M., et al. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J. Immunol. 187:10 (2011), 5408–5418.
92. Van Dyke, T.E., Hasturk, H., Kantarci, A., Freire, M.O., Nguyen, D., Dalli, J., et al. Proresolving nanomedicines activate bone regeneration in periodontitis. J. Dent. Res. 94:1 (2015), 148–156.
93. Wang, X., Zhu, M., Hjorth, E., Cortes-Toro, V., Eyjolfsdottir, H., Graff, C., et al. Resolution of inflammation is altered in Alzheimer's disease. Alzheimers Dement. 11:1 (2015), 40–50 e1–2.
94. Weiss, G.A., Troxler, H., Klinke, G., Rogler, D., Braegger, C., Hersberger, M., High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation. Lipids Health Dis., 12, 2013, 89.
95. Williams, R.O., Feldmann, M., Maini, R.N., Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha. Ann. Rheum. Dis. 59:Suppl. 1 (2000), i75–80.
96. Wolfe, F., Clauw, D.J., Fitzcharles, M.A., Goldenberg, D.L., Katz, R.S., Mease, P., et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. Hob. 62:5 (2010), 600–610.
97. Woodworth-Hobbs, M.E., Hudson, M.B., Rahnert, J.A., Zheng, B., Franch, H.A., Price, S.R., Docosahexaenoic acid prevents palmitate-induced activation of proteolytic systems in C2C12 myotubes. J. Nutr. Biochem. 25:8 (2014), 868–874.
98. Wright, H.L., Moots, R.J., Bucknall, R.C., Edwards, S.W., Neutrophil function in inflammation and inflammatory diseases. Rheumatol. Oxf. 49:9 (2010), 1618–1631.
99. Xu, Z.Z., Zhang, L., Liu, T., Park, J.Y., Berta, T., Yang, R., et al. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat. Med. 16:5 (2010), 592–597 1pp. following 7.
100. Young, A., Koduri, G., Extra-articular manifestations and complications of rheumatoid arthritis. Best. Pract. Res. Clin. Rheumatol. 21:5 (2007), 907–927.
101. Zhu, M., Van Dyke, T.E., Gyurko, R., Resolvin E1 regulates osteoclast fusion via DC-STAMP and NFATc1. FASEB J. 27:8 (2013), 3344–3353.